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B-cell development in the bone marrow is followed by specification into functional 
subsets in the spleen, including marginal zone (MZ) B-cells. MZ B-cells are classically 
characterized by T-independent antigenic responses and require the elaboration of 
distinct gene expression programs for development. Given their role in gene regulation, 
it is not surprising that microRNAs are important factors in B-cell development. Recent 
work demonstrated that deficiency of the NFκB feedback regulator, miR-146a, led to a 
range of hematopoietic phenotypes, but B-cell phenotypes have not been extensively 
characterized. Here, we found that miR-146a-deficient mice demonstrate a reduction in 
MZ B-cells, likely from a developmental block. Utilizing high-throughput sequencing and 
comparative analysis of developmental stage-specific transcriptomes, we determined 
that MZ cell differentiation was impaired due to decreases in Notch2 signaling. Our 
studies reveal miR-146a-dependent B-cell phenotypes and highlight the complex role of 
miR-146a in the hematopoietic system.
Keywords: B-cell development, marginal zone B-cells, microrna, notch signaling, gene regulation
inTrODUcTiOn
Distinct subsets of immunoglobulin-expressing B-cells have been described in the spleen, includ-
ing follicular (FO) B-cells, marginal zone (MZ) B-cells, and other, more rare, B-cell subsets. In 
general, the former subset is important for T-dependent B-cell responses to pathogens, while 
the latter is thought to play a role predominantly in T-independent B-cell responses and lipid 
antigen presentation to natural killer T cells (1). Both subsets are thought to derive from bone 
marrow-derived naïve B-cells that arrive in the spleen, where they can be recognized as immature 
transitional B-cells (T1, T2, and T3 B-cells). The development of MZ B-cells from these transitional 
subsets is thought to be regulated by several mechanisms, including (1) strength of B-cell receptor 
(BCR) signaling, (2) B-cell activating factor (BAFF)/receptor for BAFF (BAFF-R), (3) Notch2 
signaling, (4) integrins and chemokines required for MZ retention in the spleen, and (5) NFκB 
signaling (2). BCR engagement combined with BAFF/BAFF-R signaling promotes B-cell survival 
and separately MZ B development (3). While both FO and MZ B-cells depend to some degree of 
BAFF/BAFF-R and NFκB signaling, the cell surface receptor Notch2 is critical specifically for MZ 
B-cell development. Activation by the ligand Delta-like-1 expressed by endothelial cells of red 
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pulp venules catalyzes proteolytic cleavage of Notch2, releasing 
its intracellular domain, and resulting in nuclear translocation 
and downstream transcriptional effects (4).
It is likely that several other factors play roles in regulat-
ing the expression and activity of these key regulators of MZ 
B-cell development. MicroRNAs (miRNAs) are a family of small 
non-coding RNAs, 19–23  nt in length, which predominantly 
act via posttranscriptional repression of target messenger RNAs 
(mRNAs) by binding to the complimentary 3′-untranslated 
region (UTR) of the mRNA. To date, miRNAs have been 
implicated in a wide range of biologic processes, including 
hematopoietic cell development, immune function, autoimmun-
ity, and oncogenesis (5). A single miRNA can target multiple 
mRNA transcripts and target mRNAs may be controlled by 
multiple miRNAs, thus adding a layer of complexity to cel-
lular gene expression. Recent work has indicated the general 
importance of miRNAs in modulating the differentiation of 
splenic B-cell subsets. A B-cell specific knockout of Dicer, an 
endoribonuclease required for miRNA biosynthesis, resulted in a 
preferential development of MZ B-cells in mice (6). In addition 
to a general role for Dicer, specific miRNA loss or deregulation 
has been associated with various phenotypes within the B-cell 
compartment (7).
miR-146a is an NFκB-induced miRNA that shows high 
expression in spleen tissue, in particular splenic myeloid, T, 
and B-cells (8, 9). Studies using Mir146a−/− (KO) mice were 
found to have hyperactivated T FO helper cells and germinal 
centers (10), autoimmunity (8), T cell hyperactivation (11), and 
myeloid and lymphoid tumors (12) as a consequence of loss 
of feedback regulation via derepression of miR-146a targets, 
Traf6, Irak1, and Stat1 (9, 13). Although these studies have 
well characterized miR-146a’s effects in myeloid and T cell 
subsets, the effects on B-cells are not well understood. In our 
study, we found that Mir146a−/− mice show an age-independent 
defect in MZ B-cell development. We have carefully character-
ized this defect, finding that KO mice show an increase in the 
preceding transitional B-cell stages and intact splenic retention, 
indicating a block in development. Using a combination of high-
throughput sequencing, molecular biological and cellular-based 
approaches, we identified that this developmental block results 
from  deregulation of the Notch2 pathway.
MaTerials anD MeThODs
Mice
miR-146a-deficient (Mir146a−/−) mice were generated as 
described previously (8). Wild-type (WT) mice (C57B/6) and 
TCRαβ-deficient (TCRβ−/−) mice (002118) were purchased 
from Jackson laboratories and kept under pathogen-free condi-
tions at the University of California, Los Angeles. All mouse 
studies were approved by the UCLA Office of Animal Research 
Oversight.
Flow cytometry
Bone marrow, spleen, and blood were obtained from euthanized 
mice and red blood cell lysis buffer was used to lyse the single 
cell suspensions. For intracellular staining, cells were fixed in 2% 
paraformaldehyde at 37°C for 10 min and then blocked with Fc 
block for 20 min. Then, they were stained in 1× PBS with 10% FBS 
and 0.1% Triton X-100 for 20 min in the dark, and subsequently 
washed with 1× PBS with 4% FBS. Fluorochrome-conjugated 
antibodies and subset definitions are listed in Tables S1 and S2 in 
Supplementary Material. Initial spleen gating strategy is shown 
in Figure S1A in Supplementary Material. Flow cytometry was 
performed on an LSRII and data were analyzed using FlowJo 
software.
sorting of splenic B-cell subsets
Spleens pooled from three to five mice were stained according 
to FACS surface markers as noted in Table S2 in Supplementary 
Material. Cells were sorted into T1, T2, T3, FO B-cells, and MZ 
B-cells via FACS Aria.
rna sequencing (rna-seq) and analysis
Total RNA was extracted from WT and KO B-cell subsets using 
Qiazol using the Qiagen miRNEasy mini kit with additional on 
column DNAse I digestion. Following isolation of RNA, cDNA 
libraries were built using the Illumina TruSeq RNA Sample 
Preparation kit V2 (RS-122-2001). An Agilent Bioanalyzer was 
used to determine RNA quality (RIN >8) prior to sequenc-
ing. RNA-Seq libraries were sequenced at the Broad Stem Cell 
Research Center sequencing core (UCLA). Libraries were 
sequenced on an Illumina HiSeq 2000 (single-end 100bp). 
Raw sequence files were obtained using Illumina’s proprietary 
software and are available at NCBI’s Gene Expression Omnibus 
(Accession GSE93252). We first filtered out reads with low qual-
ity and reads containing sequencing adapters and then mapped 
raw reads to the mouse reference genome (UCSC mm10) with 
the gapped aligner Tophat allowing up to two mismatches. 
We supplied the UCSC mm10 gene model to Tophat as the 
reference genome annotation. Only reads uniquely aligned 
were collected. In total for all libraries sequenced, 365,022,996 
reads were uniquely mapped (corresponding to an overall 
mappability of 91.7%) and used for further analysis. Transcript 
expression levels were quantified using RPKM units (Reads Per 
Kilobase of exon per Million reads mapped) using customized 
scripts written in Perl. Differential expression analysis was 
performed using both DESeq and edgeR in R (http://www.R-
project.org). Raw read counts were used and modeled based 
on a negative binomial distribution. The multiple testing 
errors were corrected by the false discovery rate (FDR). We 
considered genes as differentially expressed if (1) the FDR was 
less than 0.05, (2) the expression ratio between two time points 
was >2×, (3) the maximal RPKM value for at least one group in 
the comparison was >1, and (4) there was agreement between 
DESeq and edgeR. These differentially expressed genes were 
then examined from the T2 to MZ and T2 to FO stages in both 
WT and KO cells. We then focused on genes only found in the 
T2 to MZ transition in WT and compared them to those in 
the T2 to MZ transition in KO B-cells. The Z-scores for each 
of these unique gene subsets were calculated, scaled, centered, 
and displayed as a heat map.
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rT-qPcr
RNA was collected from corresponding B-cell samples and reverse 
transcribed using the qScript reagent (Quanta Biosciences). 
RT-qPCR was performed with the StepOne Plus Real-Time 
PCR System (Applied Biosystems) using PerfeCTa SYBR Green 
FastMix reagent (Quanta Biosciences) or TaqMan MicroRNA 
Assay (Life Technologies). Primer sequences used are listed in 
Table S2 in Supplementary Material.
Western Blot
B220+ cells were isolated from WT and KO mice using MACS, 
treated with LPS, and cultured for 72 h. B-cells were then lysed 
with RIPA buffer (Boston BioProducts) and Halt Protease and 
Phosphatase Inhibitor Cocktail (Thermo Scientific). Equal 
amounts of protein lysate [quantification by bicinchoninic acid 
protein assay, BCA (Thermo Scientific)] were separated using 
electrophoresis on a 10% SDS–PAGE and blotted on a nitrocellu-
lose membrane. Numb Rabbit monoclonal (C29G11)(#2756) and 
β Tubulin Rabbit polyclonal (#2146) antibodies were used (Cell 
Signaling Technologies). HRP-conjugated secondary antibodies 
were from Santa Cruz Biotechnology.
luciferase reporter assay
The entire Numb 3′-UTR (1,978−3,382  nt; GenBank ID: 
NM_001136075) containing the miR-146a site was cloned into 
the pmiRGlo dual luciferase vector (Promega). The miR-146a 
seed sequence AGTTCTCA (2,596−2,603  nt) was mutated to 
CTCATAGT and also cloned into pmiRGlo. A similar strategy 
was used for cloning a 2  kb segment of the Notch2 3′-UTR 
(7,584−9,592 nt; GenBank ID: NM_010928) immediately down-
stream of the stop codon. The putative miR-146a seed sequence 
GTTCTCA (8,815−8,821  nt) was mutated to CAGTCTT and 
also cloned into pmiRGlo. Standard PCR and cloning methods 
were employed. TargetScan was used to predict miR-146a 
seed sequences. The Traf6 3′-UTR was cloned as previously 
described (14). HEK-293T cells were co-transfected with lucif-
erase reporter vectors, with or without miR-146a expression 
vector using BioT transfection reagent (Bioland Scientific) as 
per the manufacturer’s instructions. Cells were lysed after 48 h, 
substrate was added, and luminescence was measured on a 
Glomax-Multi Jr (Promega).
statistical analyses
Figures are graphed as mean with the SD of the mean for continu-
ous numerical data. Dichotomized or ordinal-type histopatho-
logic data are presented using bar graphs. Data were analyzed 
with two-tailed Student’s t-test, conducted using GraphPad Prism 
software, applied to each experiment as described in the figure 
legends. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
resUlTs
Deficiency of mir-146a results in 
Decreased MZ B-cells in the spleen
Previous studies have shown that Mir146a−/− mice show age-
dependent changes in splenic cellularity and activated T  cell 
phenotypes, starting from 2 to 4 months (10, 11). This is followed 
by autoimmune inflammatory disease, splenomegaly, lymphad-
enopathy, and myeloproliferation, and at very advanced ages 
by splenic myeloid sarcomas, lymphomas, and bone marrow 
failure (12). Given the high expression of miR-146a in B-cells 
and features of autoimmune disease in KO mice, we examined 
splenic B-cell subsets to better characterize miR-146a’s effect on 
B-cell maturation. Beginning with young mice, we confirmed 
that increases in total splenic cellularity (Figure 1A) and B220+ 
B-cells (Figure 1B) were apparent as early as 8–12 weeks old. 
We characterized immature transitional B-cells (T1, T2, and 
T3), FO cells, MZ B-cells, and B1 cells and compared them 
between WT and KO mice (Figure 1C) (15). Increased percent-
ages and numbers in precursor T1, T2 (Figure 1D; Figure S2 
in Supplementary Material), T3, and B1 cells (Figures S1C,D 
and S2 in Supplementary Material) were seen starting from 8 to 
12 weeks in KO compared to WT. In addition, the overall num-
ber of FO B-cells started to trend higher in KO mice at 8 weeks 
of age and statistically significant differences were observed 
at 12  weeks of age in KO mice (Figure S2 in Supplementary 
Material). In contrast, MZ B-cells showed a significant decrease 
as early as 8  weeks of age (Figure  1D). This defect persisted 
until at least 18  weeks of age in the KO mice (Figure S3 in 
Supplementary Material), after which expansion of the myeloid 
compartment began to take over in KO spleens (12). In addition, 
an alternative gating analysis (Figure S1B in Supplementary 
Material) (1) showed that this defect was also present in MZ 
precursor (MZP) cells, again confirming a deficiency in the MZ 
development pathway (Figure S1E in Supplementary Material). 
Together, these results indicate a specific defect in the MZ subset 
of splenic B-cells, with an increase in T1 and T2 transitional 
zone B-cells, suggestive of defective differentiation into MZ 
B-cells in KO mice.
Decreased MZ B-cells in  
mir-146a-deficient Mice are Due to 
spleen-intrinsic Defect and not Bone 
Marrow Development Failure or lack 
of splenic retention
To fully characterize the origin of differences in splenic B-cell 
subsets between WT and KO mice, we looked upstream into 
the bone marrow to assess deficiencies in B-cell development. 
At the early ages of 8 and 12 weeks, there were no statistically 
significant differences in total live cells (Figure  2A) or B220+ 
B-cells (Figure  2B). We subsequently characterized bone mar-
row B progenitor cells (15) in WT and KO mice (Figure  2C). 
Fractions A–E in young mice remained similar, although at 
12 weeks fraction A showed a decrease in KO mice (Figure 2D), 
which may represent the beginning of myeloproliferative disease 
or faster flux through this particular stage of development (12, 
16). Hardy Fraction F cells, which represent mature bone mar-
row B-cells as well as recirculating cells, showed a decrease in 
KO mice, likely representing a decreased recirculating fraction 
secondary to increased retention of overall B-cells in the spleen. 
To ensure that this decrease in pre–pro B-cells was not due to 
decreases in hematopoietic stem cell/progenitor development, 
FigUre 1 | Mir146a−/− mice exhibit an increase in total splenic B-cells and immature splenic subsets, except exhibit a defect in marginal zone (MZ) 
B-cells. Cell numbers of (a) total live cells (*p = 0.015, ****p < 0.0001) and (B) B220+ B-cells (*p = 0.021, ****p < 0.0001) are shown in young mice, ages 8 weeks 
(n = 8–9 mice/group) and 12 weeks (n = 12–14 mice/group). Values are mean ± SD. (c) Representative FACS plots show maturing B-cell subsets in spleens of 
wild-type (WT) mice and Mir146a−/− knockout (KO) mice at 12 weeks. (D) Analysis of spleen subsets from WT mice and KO mice are shown at early ages 
(n = 12–14/group). Increases in the transitional T1 (***p = 0.0001) and T2 (*p = 0.043, ***p = 0.0003) B cells are shown. MZ B-cells are decreased in KO at ages 
8 weeks (**p = 0.008), 12 weeks (****p < 0.0001). Values are mean ± SD.
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we examined hematopoietic stem cells (HSC), multipotent 
progenitors (MPP), lymphoid-primed multipotent progenitors 
(LMPP), early lymphoid (ELP), and common lymphoid (CLP) 
progenitors, and found no difference in young mice (Figures 
S4A,B in Supplementary Material), similar to prior work (16).
In addition, we explored the possibility that a defect in MZ 
B-cells in KO mice may have been due to a lack of retention of 
these cells in the splenic niche. However, examination of the 
peripheral blood (17) showed no difference in MZ B-cells between 
WT and KO mice (Figure 3A). Also, there were no differences in 
MZ B-cells in lymph nodes (Figure 3B). However, overall B220+ 
cells and FO cells were increased in KO vs. WT, as consistent with 
spleen findings. Furthermore, because it is known that MZ cells 
may differentiate into plasmablasts after interacting with antigens 
presented from macrophages, dendritic cells, or neutrophils, we 
examined this possibility. It is known that myeloid lineage cells 
in the spleen of KO mice are significantly increased in older KO 
mice (8, 12, 16). Hence, we performed FACS analysis for mac-
rophages, dendritic cells, and neutrophils in young 12-week-old 
mice and found that they were similar in WT and KO at this 
early age (Figure  3C). Furthermore, plasmablasts were then 
assessed in WT and KO spleens, and also following stimulation 
with LPS, CpG, or CD40 + IL4, and were not statistically differ-
ent (Figure 3D). Together with a lack of significant changes in 
FigUre 2 | Mir146a−/− mice show intact bone marrow B-cell development. Cell numbers of (a) total live cells (p = nss) and (B) B220+ B-cells (p = nss) are 
shown in young mice, ages 8 weeks (n = 8 mice/group) and 12 weeks (n = 12–14 mice/group), respectively. Values are mean ± SD. (c) Representative FACS plots 
show bone marrow B progenitors cells (Hardy Fractions) in bone marrow of WT (top panel) and KO mice (bottom panel) at 12 weeks. (D) Analysis of B progenitor 
cell subsets from WT and KO mice at early ages (8 and 12 weeks). Fraction A (*p = 0.006), fraction F at 8 weeks (*p = 0.025) and 12 weeks (*p = 0.001). Values are 
mean ± SD.
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bone marrow development, these findings suggest a local spleen 
intrinsic defect leading to decreased MZ B-cell development.
Next, we explored whether the decrease in MZ B-cells was 
related to a developmental defect or due to an altered prolifera-
tion and/or apoptosis of MZ B-cells. Using intracellular Ki67 
staining in conjunction with staining for B-cell developmental 
subsets, we determined that the proportion of Ki67 positive cells 
was statistically unchanged between WT and KO MZP and MZ 
B-cells (Figure 3E). Similarly, Annexin V staining revealed no 
statistically significant differences in apoptosis of these B-cell 
subsets (Figure 3F). In summary, these data strongly support 
the idea that the defect in MZ B-cells in Mir146a−/− mice is due 
to a developmental block in maturation of T2 cells into MZ 
B-cells.
FigUre 3 | continued 
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mir-146a-Deficient B-cells exhibit altered 
gene expression during Maturation from 
Transitional to MZ stages
To dissect the mechanistic basis of the observed MZ B-cell 
block in development, we undertook gene expression analyses 
of the splenic B-cell subsets. First, we examined whether miR-
146a was differentially expressed in different splenic B-cells. 
Indeed, RT-qPCR revealed that MZ B-cells had the highest 
levels of miR-146a expression, with expression noted in all 
subsets (Figure 4A). Next, we performed RNA-Seq on WT and 
KO transitional (T1 and T2), MZ and FO B-cell subsets with 
FigUre 3 | lower Mir146a−/− marginal zone (MZ) B-cells are likely due to a spleen intrinsic developmental block. (a) Peripheral blood B220+ cells show 
no statistically significant difference in circulating MZ or follicular cells (n = 4 mice/group). (B) Mature B-cell subsets are shown in peripheral lymph nodes (B220+ 
**p = 0.002; FO **p = 0.001) (n = 7 mice/group). (c) Splenic macrophages, dendritic cells, and neutrophils show no differences in WT vs. KO (n = 7 mice/group). 
(D) CD138+ plasmablasts are shown in unstimulated spleens (0 h) and 96 h poststimulation with CD40 + IL4, with no significant differences (repeated in duplicate). 
(e) Intracellular Ki67 and (F) Annexin V staining are shown for MZ and MZ precursor (MZP) cells (n = 7 mice/group).
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biological replicates. Surprisingly, when we directly compared 
the corresponding B-cell stages between the WT and KO mice, 
only three to six genes showed differential expression. Of this 
limited group of differentially expressed genes, none were pre-
dicted miR-146a targets. The limited numbers of differentially 
expressed genes using direct comparison of subsets led us to 
consider alternate approaches. Given that there are very signifi-
cant changes occurring in gene expression as a T2 cell commits 
to a MZ fate, we hypothesized that miR-146a alters the set of 
genes that are changing during this cell fate commitment. To this 
end, we utilized an alternative analysis comparing transitions 
between developmental stages of immune cells, similar to an 
approach that has been previously described (18). Interestingly, 
the transition from T2 to FO B-cells showed only 57 or 25 
differentially expressed genes in the WT and KO, respectively 
(Figure 4B). In contrast, the T2 to MZ transition showed 1,270 
or 1,183 differentially expressed genes in WT and KO, respec-
tively (Figure 4B), indicating a large change in gene expression 
needed for commitment to the MZ over the FO fate. Focusing 
on the T2 to MZ transition, we compared the differentially 
expressed genes in WT and KO transcriptomes (Figure  4C). 
WT and KO mice showed 1,004 differentially expressed genes 
in common during the T2 to MZ transition; in addition, there 
were 266 differentially expressed genes unique to WT mice and 
179 unique to KO mice. These unique gene subsets formed two 
clusters that either increased or decreased in expression during 
the T2 to MZ transition (Figure 4D). Interestingly, the subset 
unique to the KO mice showed the majority of genes increasing, 
although these genes as a class were not enriched for predicted 
miR-146a targets (data not shown).
Notch2 activity is Diminished  
in mir-146a-deficient MZ B-cells
To further examine what genes may be changing, we analyzed 
transcriptional targets of pathways known to play a role in 
MZ B-cell differentiation, namely, Notch2, BAFF, and NFκB 
(Figure 4E). Several known transcriptional targets of the Notch2 
pathway showed lesser fold change of reads per kilobase of 
transcript per million mapped reads (RPKMs) between T2 and 
MZ cells in KO compared to WT mice (Figure 3E, red). On the 
other hand, BAFF-associated genes (gray) and NFκB-associated 
genes (blue) did not show a consistent change toward reduced or 
increased fold change at the T2–MZ transition between WT and 
KO. Because the RNA-Seq data demonstrated decreased expres-
sion of Notch2 targets in KO MZ B-cells, we further validated 
these findings by examining Notch2 transcriptional targets by 
RT-qPCR. First, we used bacterial lipopolysaccharide (LPS) to 
strongly induce miR-146a expression (9, 16) and screened for 
Notch2 transcription targets using RT-qPCR at 72 h poststimula-
tion. RT-qPCR revealed that KO B-cells showed significantly 
decreased expression of Notch2 transcriptional targets Hes1, Hes5, 
and Dtx4 (Figure 4F) (19, 20). We then examined expression of 
these candidate genes in primary splenic B-cell subsets, reveal-
ing reductions of Hes1 and Hes5 and a trend toward reduced 
Dtx4, specifically in MZ B-cells lacking miR-146a (Figure 4G). 
Together, these data suggest that KO mice have an altered gene 
expression profile during the T2–MZ transition, particularly 
downstream of Notch2, corresponding with the increased expres-
sion of miR-146a in the WT MZ population.
Interestingly, Notch2 itself showed a mild but significant 
reduction at the mRNA level in KO MZ B-cells (Figure  5A). 
To characterize the effect of miR-146a deficiency on Notch2 
protein, we utilized flow cytometry analysis. Notch2 is initially 
expressed as a surface receptor, and is internalized, cleaved, and 
endocytosed upon activation. Cell-surface expression of the 
transmembrane Notch2 receptor was not altered in the absence of 
miR-146a (Figure S5 in Supplementary Material). Subsequently, 
we examined intracellular expression of Notch2 in WT mice, 
noting that the highest expression of intracellular Notch2 was 
found in MZ and MZ precursor cells (Figure 5B). In line with a 
downstream effect on Notch2-mediated transcription, intracel-
lular staining for Notch2 showed a significant decrease in KO 
MZ and MZP B-cells (Figures 5C,D). We then confirmed these 
findings via Western Blot. To obtain enough protein for analysis, 
we used LPS to stimulate the WT and KO bulk B-cells and found 
Notch2 protein was decreased in KO compared to WT cells at 
72 h poststimulation (Figure 5G).
FigUre 4 | continued  
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rna sequencing (rna-seq) reveals differentially expressed mir-146a-dependent genes at the T2 to MZ transition. (a) Representative RT-qPCR 
showing relative expression levels of miR-146a in WT T1, T2, MZ, and FO splenic B-cell subsets per cell. (T1-MZ ***p = 0.0002; T2-MZ **p = 0.0015; MZ-FO 
***p = 0.0009; repeated in duplicate). Values are mean ± SEM. (B) Schematic diagram depicting the number of differentially expressed genes between the T2 to MZ 
and T2 to FO transitions in both WT and KO mice. (c) Venn diagram comparing and contrasting the number of genes unique to and shared between the T2 to MZ 
transition in WT and KO mice. (D) Heat maps from the RNA-Seq data showing differentially expressed genes unique to the T2 to MZ transition in WT vs. genes 
unique to the T2 to MZ transition in KO (−1 and −2 denote replicates). (e) A waterfall plot of the RNA-Seq data displaying notable genes in three signaling pathways 
influencing MZ B-cell development. (F) Representative RT-qPCR analysis of Notch2-associated genes in bulk splenic B-cells 72 h after LPS stimulation repeated in 
duplicate (Hes1 **p = 0.0099; Hes5 *p = 0.032; Dtx4 *p = 0.013). (g) Quantified relative expression of Notch2-associated genes in splenic B-cell subsets using 
RT-qPCR (Hes1 T2 **p = 0.0082, MZ **p = 0.0014, FO **p = 0.0019; Hes5 T1 ***p = 0.001, MZ *p = 0.011; repeated in duplicate).
FigUre 4 | continued
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A similar analysis for NFκB transcriptional targets (Figures 
S6A,B in Supplementary Material) and for two known miR-
146a targets, Traf6 and Irak1 (Figures S6C–F in Supplementary 
Material) (8, 9) failed to show statistically significant differences. 
In addition, a gene set enrichment analysis (GSEA) of the T2 to 
MZ differentially expressed genes in KO did not show enrich-
ment in NFκB target genes (data not shown). Together, these data 
demonstrate that the decrease in MZ B-cells is most likely due to 
the reduction in Notch2 activity and that miR-146a regulates the 
levels of Notch2.
numb, a regulator of the notch2 Pathway, 
is a Direct Target of mir-146a
Previous studies have indicated that the adaptor protein Numb, 
a negative regulator of Notch, contains a predicted miR-
146a-binding site within its 3′-UTR, but direct targeting has 
been observed by some groups, but not others (21, 22). One of 
the canonical functions of Numb is to inhibit Notch signaling 
by recruiting ubiquitin ligases to degrade cell surface-associated 
and intracellular Notch proteins (23). Numb may also directly 
bind to the notch intracellular domain (NICD) in the cytoplasm, 
thus preventing translocation into the nucleus and subsequent 
downstream transcription of Hes1, Hes5, and Hey1 (19, 24). Here, 
we hypothesized that if Numb is derepressed in KO MZ B-cells, 
it may lead to degradation of Notch2 and subsequent inhibition 
of the gene expression program that is required for MZ B-cell 
development. Using intracellular FACS staining, we found that 
Numb was more highly expressed in KO transitional T2 cells 
(Figures  5E,F). Hence, this increase in Numb expression in 
the T2 subset developmentally precedes the decrease in Notch2 
expression in MZP and MZ B-cells, but the reciprocal relation-
ship was not observed in the same cell types (Figures 5C,D). We 
then confirmed that Numb protein was increased by Western Blot 
in KO LPS-stimulated B-cells, consistent with a lack of repression 
by miR-146a (Figure 5G).
As mentioned above, the Numb 3′-UTR contains predicted 
miR-146a binding sites (Figure 5H). To assess direct repression 
of Numb by miR-146a, we cloned a ~1,300-bp fragment of the 
Numb 3′-UTR into the pmiRGlo luciferase reporter. Repression 
of the luciferase reporter was observed with co-transfection of 
miR-146a, and this repression was abolished upon mutation of the 
miR-146a seed sequence (see Materials and Methods). Of note, 
although Notch2 also contained a predicted miR-146a-binding 
site within its 3′-UTR, luciferase activity was not repressed 
(Figures  5H,I). Together, our findings indicate that Numb is a 
direct target of miR-146a. Downstream, there is inhibition of 
Notch2 and the gene expression program required for MZ B-cell 
development. The relationship between miR-146a-mediated 
inhibition of Numb and Notch2 regulation by Numb requires 
further study.
mir-146a regulation of MZ B-cell 
Development is T-cell independent
Given that T cells show profound abnormalities in the Mir146a −/− 
mice, another possibility is that there is a T-dependent pathway 
that leads to increased numbers of FO cells and decreased num-
bers of MZ B-cells. To test this, we bred mice deficient in αβ T 
cell receptor (TCRβ −/−) onto Mir146a −/− mice to make double 
knockouts Mir146a −/−, TCRβ −/− (DKO), and examined splenic 
subsets. As expected, TCRβ −/− and DKO showed higher number 
of B220+ cells (Figure 6A), given the deficiency of T cells skewing 
the immune populations. Hence, to compare between genotypes, 
we examined the percentage of B220+ cells for all given splenic 
subsets (i.e., T2, MZ shown). The T2 subset was similar in KO and 
DKO mice (Figure 6B), and we noted no differences in MZ subsets 
between Mir146a −/− and DKO, indicating that this defect was not 
T cell dependent (Figures 6C,D). Furthermore, when comparing 
DKO with TCRβ −/− mice, DKO displayed statistically significant 
decreases in MZ cells, suggesting that the phenotype is indeed 
an effect of miR-146a in B-cells (Figures 6C,D). Taken together, 
our results indicate MZ deficit seen in miR-146a-deficient mice 
is likely B-cell intrinsic and is not dependent on the presence of 
hyperactivated T cells.
DiscUssiOn
Here, we found that miR-146a deficiency has an effect on the 
differentiation of B-cells in the spleen. miR-146a is expressed 
more highly in MZ B-cells than in any other splenic B-cell subset, 
suggesting an important role in these cells. Indeed, the MZ B-cell 
subset in Mir146a−/−  mice is markedly reduced. The T1 and T2 
subsets that developmentally preceded MZ B-cells are higher in 
the spleen. Peripheral blood and lymphoid MZ B-cells are similar, 
suggesting that MZ splenic retention is intact. Furthermore, dif-
ferentiation into plasmablasts is similar between KO and WT, and 
alterations in proliferation and apoptosis do not account for the 
MZ B-cell defect. Hence, we felt that this MZ B-cell abnormal-
ity arises from defective development of this subset within the 
spleen. Exploring the molecular mechanism of this block, we 
found a reduction in intracellular Notch2 and its downstream 
FigUre 5 | continued  
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FigUre 6 | Deficiency of marginal zone (MZ) B-cells in Mir146a−/− mice is not T cell dependent. Comparison of percentages of (a) total B220+ B-cells 
(****p < 0.0001), (B) T2 subset, and (c) MZ B-cells (**p = 0.002, *p = 0.022) in Mir146a−/− (146a KO), Mir146a−/− TCRβ−/− (DKO), and TCRβ−/− (TCRβ KO) mice. 
All non-annotated comparisons are not statistically significant (n = 4–7 mice/group, repeated in duplicate). (D) Representative FACS plots showing the MZ fraction in 
spleen in three mice groups.
Mir146a−/− B-cells show decreased notch2 and increased numb, a direct target of mir-146a. (a) Representative RT-qPCR quantification of Notch2 
expression in splenic B-cell subsets in wild-type (WT) vs. KO (T2 **p = 0.0057, marginal zone (MZ) ***p = 0.0002, FO *p = 0.016; repeated in duplicate). (B) 
Representative FACS overlay of intracellular Notch2 expression in WT B-cell subsets. (c) Quantitation of median fluorescence intensity (MFI) of intracellular staining 
of Notch2 in T2, MZ precursors (MZP), and MZ B-cells (MZP *p = 0.035; MZ *p = 0.014; n = 3–4 mice/group, repeated in duplicate). (D) Representative overlapping 
histograms of Notch2 MZ subsets in WT vs. KO mice. (e) Quantitation of MFI of intracellular staining of Numb in T2, MZP, and MZ B-cells (T2 **p = 0.0083; 
n = 4–5 mice/group). (F) Representative overlapping histogram of T2 Numb in WT vs. KO. (g) Western blot shows increased Numb protein and decreased Notch2 
protein in LPS-stimulated splenic B-cells from WT and KO mice. β-Tubulin was used as a loading control and fold change was calculated using ImageJ (repeated in 
duplicate). (h) Numb 3′-untranslated region (UTR) and Notch2 3′-UTR containing the putative seed sequences of miR-146a (yellow box) are shown. (i) Luciferase 
assays quantitating repression with MGP/miR-146a relative to MGP alone for each of the UTRs depicted. Each measurement is representative of firefly luciferase 
normalized to renilla luciferase and was performed in triplicate, with the experiment repeated at least three times (Traf6 vs. Vector, ***p = 0.0004; Numb vs. Vector, 
**p = 0.0016; Numb vs. mutated Numb, *p = 0.012; Notch2 vs. mutated Notch2). All values are mean ± SEM.
FigUre 5 | continued
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transcriptional targets, implicating miR-146a-mediated regula-
tion of a pathway required for the development of MZ B-cells. In 
identifying this pathway, we utilized a novel method of analysis, 
where we compared developmental transition-related transcrip-
tomic changes between WT and KO mice. This was productive, as 
it highlighted many more genes that were potentially important 
than a simple cross-comparison between WT and Mir146a−/− 
cells at a particular developmental change.
Because miR-146a is an important regulator of NFκB signal-
ing, we wanted to understand whether the MZ B-cell phenotype 
that we observed is a consequence of hyperactivated NFκB. 
In myeloid and classic CD4+ and CD8+ T cells, miR-146a is 
induced by NFκB, and in turn targets the upstream adapter 
proteins Traf6 and Irak1, to cause negative feedback regulation of 
the NFκB response (8, 11). Thus, an overall increase in proinflam-
matory NFκB, as a consequence of loss of negative feedback, is 
responsible for many of the phenotypes seen in Mir146a−/− mice. 
Knocking out the classical NFkB p50 in these mice resulted in 
a rescue of the myeloproliferative phenotype, but did not com-
pletely rescue the autoimmune pathology (12) and only partially 
corrected hyperactivation of T cells (11). We did not find telltale 
increases in key NFκB transcriptional targets at the RNA level 
and did not observe changes in Irak1 or Traf6 protein. However, 
Notch2 was clearly affected. NFκB and Notch2 appear to cooper-
ate in MZ B-cell development as demonstrated by heterozygous 
knockout Notch2+/− p50+/− mice which show loss of MZ B-cells 
without affecting the FO B-cell population (25). Interestingly, 
non-canonical NFκB pathway via Relb was also shown to be 
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important for development of MZ B-cells (26, 27). In our data 
set, NFκB response genes generally are downregulated at the 
T2-MZ transition, which would be consistent with miR-146a 
upregulation at that transition. However, we did not see direct 
evidence of these response genes or of known miR-146a targets 
(Traf6 and Irak1) being dysregulated in Mir146a−/− mice. This 
would indicate that the main thrust of miR-146a activity is not 
focused on this pathway in MZ B-cells. miR-146a likely targets 
different pathways in different immune cells/tissues. Indeed, it 
was shown that in T regulatory cells (Tregs), miR-146a is highly 
expressed and likely targets Stat1 in the interferon gamma path-
way (IFNγ) (13). Our own recent work demonstrated Egr1 to 
be a novel target of miR-146a in Myc-driven B-cell tumors (14). 
Hence, a multiplicity of targets for miR-146a exists in different 
cell types and under different contexts.
Our data demonstrate that Numb is a possible novel target of 
miR-146a in B-cells. Numb is increased in miR-146a-deficient 
T2 cells, which immediately developmentally precede MZ cells. 
Although Numb is a known regulatory of Notch, the recipro-
cal relationship between Numb and Notch2 is not seen in the 
same cells. Hence, the connection between miR-146a, Numb, 
and Notch2 cannot be definitively made. Given our findings, 
we speculate that a combination of the cellular kinetics of dif-
ferentiation, balance between production and degradation of 
intracellular Notch2, and asymmetric cell division mediated 
by Numb (24) may underlie the relationships that we have 
observed. Indeed, the rates of production and degradation 
of intracellular Notch2 may be dramatically different once a 
cell has committed to the MZ B-cell fate. However, teasing 
out the nature of these relationships will take additional work 
and effort.
We also found that the MZ phenotype is T cell independent, 
supporting a B-cell intrinsic mechanism for the MZ defect in 
Mir146a−/− mice. Other investigators have also endorsed the idea 
that MZ B-cell development is largely T-independent (2). In addi-
tion, the conditional knockout of Dicer in B-cells specifically led 
to an increase in MZ B-cells and decreased FO B-cells, suggesting 
that miRNAs can drive B-cell intrinsic phenotypes independent 
of T cells (6).
Our report demonstrates a specific B-cell subset abnormality 
in Mir146a−/− mice, and we have identified a likely novel target 
in the MZ B-cell lineage. Our future studies will focus on how 
Mir146a−/− B-cells contribute to the autoimmune phenotype, 
manifested by end-organ inflammation and production of anti-
double-stranded DNA antibodies (8) characteristic of murine 
and human systemic lupus erythematosus (SLE). As the function 
of MZ B-cells in responses to specific antigen types has been 
postulated, it will be important to determine how this reduction 
in MZ B-cells, and the corresponding increase in FO cells, have 
functional consequences in tilting the balance toward clinical 
autoimmunity. Interestingly, miR-146a is expressed at low levels 
in peripheral blood mononuclear cells (PBMC) from patients 
with SLE (28) and treatment with chemically modified miR-146a 
agonists improved pulmonary hemorrhage in a pristane-induced 
lupus mouse model (29). Hence, it will be highly interesting to 
determine how miR-146a deficiency in B-cells contributes to 
autoimmune pathogenesis in murine models and ultimately in 
human disease.
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